indapamide has been researched along with Vascular Diseases in 6 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with type 2 diabetes mellitus have markedly increased risks of developing vascular diseases." | 2.71 | [ADVANCE study: objectives, design and current status]. ( Chalmers, J, 2003) |
| "Pharmacological treatment of hypertension represents a cost-effective way of preventing cardiovascular and renal complications." | 2.43 | Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. ( Waeber, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Wang, D | 1 |
| Chalmers, J | 4 |
| Jun, M | 1 |
| Zoungas, S | 1 |
| Marre, M | 2 |
| Hamet, P | 2 |
| Harrap, S | 1 |
| Mancia, G | 2 |
| Poulter, NR | 1 |
| Cooper, ME | 2 |
| Woodward, M | 2 |
| Selvin, E | 1 |
| Rebholz, CM | 1 |
| van Steen, SC | 1 |
| Li, Q | 1 |
| Colagiuri, S | 1 |
| Williams, B | 1 |
| Grobbee, DE | 1 |
| DeVries, JH | 1 |
| Brugts, JJ | 1 |
| Ninomiya, T | 1 |
| Boersma, E | 1 |
| Remme, WJ | 1 |
| Bertrand, M | 1 |
| Ferrari, R | 1 |
| Fox, K | 1 |
| MacMahon, S | 1 |
| Simoons, ML | 1 |
| Waeber, B | 1 |
| Duka, I | 1 |
| Bakris, GL | 1 |
1 review available for indapamide and Vascular Diseases
| Article | Year |
|---|---|
Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
3 trials available for indapamide and Vascular Diseases
| Article | Year |
|---|---|
Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; beta 2-Microglobulin; Biomarkers; Cause of Death; Creatinine; Cystati | 2020 |
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; | 2018 |
[ADVANCE study: objectives, design and current status].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Press | 2003 |
2 other studies available for indapamide and Vascular Diseases
| Article | Year |
|---|---|
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diabetic Angiopathies; Drug Therapy, Combi | 2009 |
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Human | 2007 |